Nijmegen, May 31, 2021 As of May 2021, CbusineZ will join Orikami Group BV, alongside existing investor Healthy.Capital. Both investors enable Orikami to roll out the product MS sherpa to clinical practice and also accelerate…
Our mission - to improve 100 million lives before 2030 by enabling personalized healthcare.
We believe health data is underutilized. We use real-world patient data to enable personalized healthcare paths for our clients to improve their quality of life. Therefore, we develop digital biomarkers.
Our solutions deliver better outcomes and affordable healthcare.
VALUE of Digital Biomarkers
Clinical validated digital biomarkers provide objective data that provides clinically significant results. This enables decision support to clinicians and will optimize patients’ health paths. This is needed to innovate healthcare and increase the efficiency of the healthcare ecosystems.